Literature DB >> 10663483

The role of MRI in screening for neurogenic hypertension.

D Johnson1, S C Coley, J Brown, I F Moseley.   

Abstract

Neurovascular compression (NVC) of the left ventrolateral medulla (VLM) has been implicated as a cause of essential hypertension. We investigated whether high-resolution MRI of the posterior cranial fossa could identify patients with essential hypertension who may benefit from surgery. A retrospective analysis of imaging and clinical records from 162 patients was performed. There were 38 patients with essential hypertension and 124 who were normotensive. Contact or compression of the VLM was present in 42.1 % (16/38) of the hypertensive group on the left and 47.3 % (18/38) on the right. In the normotensive group it was seen in 32.2 % (40/124) on the left and 26.6 % (33/124) on the right. There was no significant difference between the hypertensive and control groups with regard to contact or compression of the left VLM. The results support the contention that neurovascular compression (NVC) of the left or right VLM is a common finding on MRI in normotensive individuals. We therefore believe that high-resolution MRI cannot be used as a screening tool to identify patients who may benefit from surgery.

Entities:  

Mesh:

Year:  2000        PMID: 10663483     DOI: 10.1007/s002340050023

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  2 in total

1.  Neurovascular contact of the brain stem in hypertensive and normotensive subjects: MR findings and clinical significance.

Authors:  C Thuerl; L C Rump; M Otto; J T Winterer; B Schneider; L Funk; J Laubenberger
Journal:  AJNR Am J Neuroradiol       Date:  2001-03       Impact factor: 3.825

2.  3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension.

Authors:  Panagiota Manava; Ramin Naraghi; Roland Schmieder; Rudolf Fahlbusch; Arnd Doerfler; Michael M Lell; Michael Buchfelder; Peter Hastreiter
Journal:  Clin Neuroradiol       Date:  2020-05-27       Impact factor: 3.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.